<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749658</url>
  </required_header>
  <id_info>
    <org_study_id>GCRC 10047</org_study_id>
    <secondary_id>K01DA019446</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00749658</nct_id>
  </id_info>
  <brief_title>Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence</brief_title>
  <acronym>ChanBan</acronym>
  <official_title>Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this proposal is to elucidate effects of bupropion SR + varenicline on&#xD;
      smoking-cessation related processes in early abstinence using a human laboratory model. A&#xD;
      within-subjects design will be used to assess the additive effects of bupropion and&#xD;
      varenicline in 48 treatment seeking smokers [bupropion SR (300 mg/day)+placebo, varenicline&#xD;
      (2 mg/day+placebo, and bupropion SR (300 mg/day)+varenicline (2 mg/day)]. Outcomes include&#xD;
      withdrawal and craving, cognition, stress tolerance, anxiety, the reinforcing effects of&#xD;
      smoking, and smoking topography.&#xD;
&#xD;
      Hypotheses: We hypothesize that greatest treatment effects will be observed in the bupropion&#xD;
      SR+varenicline group followed by varenicline+placebo and bupropion SR+placebo groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nicotine Withdrawal and Craving</measure>
    <time_frame>Change from Base line to 33 weeks</time_frame>
    <description>Subjects were analyzed by how they self reported withdrawal or craved cigarettes during treatment Subjects self reported during study visits along with surveys</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Nicotine Withdrawal</condition>
  <arm_group>
    <arm_group_label>Bupropion + Placebo Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>upropion + Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupropion + Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.</description>
    <arm_group_label>Bupropion + Placebo Varenicline</arm_group_label>
    <arm_group_label>upropion + Varenicline</arm_group_label>
    <other_name>Zyban</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
    <arm_group_label>Bupropion + Placebo Varenicline</arm_group_label>
    <arm_group_label>upropion + Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years and up.&#xD;
&#xD;
          2. Smoked at least 10 cigarettes/day for at least 1 year.&#xD;
&#xD;
          3. English speaking and reading.&#xD;
&#xD;
          4. Females who are of childbearing potential must practice effective contraception and&#xD;
             meet the following criteria:&#xD;
&#xD;
               1. Are instructed to avoid pregnancy through 30 days after the last dose of study&#xD;
                  medication.&#xD;
&#xD;
               2. Have a negative urine pregnancy test at baseline.&#xD;
&#xD;
               3. Agree to use of the birth control methods listed: an oral contraceptive agent, an&#xD;
                  intrauterine device (IUD), an implantable contraceptive (e.g., Norplant), or an&#xD;
                  injectable contraceptive (e.g., Depo-Provera) for at least one month prior to&#xD;
                  entering the study and will continue its use through at least 30 days after the&#xD;
                  last dose of the study medication. A barrier method of contraception (e.g.,&#xD;
                  condom or diaphragm with spermicide) while participating in the study and 30 days&#xD;
                  after the last dose of study medication.&#xD;
&#xD;
          5. Willingness to not use illicit drugs during study period including marijuana.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unstable medical condition.&#xD;
&#xD;
          2. Unstable angina, myocardial infarction, or coronary angioplasty within the past 3&#xD;
             months or an untreated cardiac dysrhythmia.&#xD;
&#xD;
          3. Personal history of seizures.&#xD;
&#xD;
          4. Closed head trauma with any loss of consciousness or amnesia in the last 5 years.&#xD;
&#xD;
          5. A history of closed head trauma with &gt; 30 minutes of loss of consciousness or amnesia&#xD;
             or resulting in skull fracture or subdural hematoma/brain contusion.&#xD;
&#xD;
          6. A history of psychosis, bipolar disorder, bulimia or anorexia nervosa.&#xD;
&#xD;
          7. Current depression as assessed by Center for Epidemiologic Studies Depression Scale&#xD;
             (CES-D).&#xD;
&#xD;
          8. Medications that might affect the outcome measures of nicotine reward, cognition,&#xD;
             anxiety, and stress will also be a basis for exclusion. These medications include&#xD;
             psychotropic drugs (i.e., anti-psychotic, anti-depressant, anti-anxiety, or&#xD;
             stimulant), anti- hypertensive agents (e.g., beta-blockers), and other drugs that can&#xD;
             influence the outcome domains.&#xD;
&#xD;
          9. Active substance abuse other than nicotine.&#xD;
&#xD;
         10. Used an investigational drug within the last 30 days.&#xD;
&#xD;
         11. Are currently using a behavioral or pharmacologic tobacco treatment.&#xD;
&#xD;
         12. Use of bupropion or varenicline in the previous 30 days.&#xD;
&#xD;
         13. Current (past 14 days) use of antipsychotic or antidepressant medications.&#xD;
&#xD;
         14. An allergy to bupropion or varenicline.&#xD;
&#xD;
         15. Untreated hypertension or baseline systolic blood pressure &gt; 180 or diastolic &gt; 100.&#xD;
&#xD;
         16. Impaired kidney function (creatinine clearance &lt; 30).&#xD;
&#xD;
         17. Having plans to leave the immediate geographical area within 2 months.&#xD;
&#xD;
         18. Unwillingness or inability to give written informed consent.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc E Mooney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota, Tobacco Use Research Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tobaccoresearch.umn.edu</url>
    <description>Tobacco Use Research Center</description>
  </link>
  <reference>
    <citation>Ingersoll KS, Cohen J. Combination treatment for nicotine dependence: state of the science. Subst Use Misuse. 2005;40(13-14):1923-43, 2043-8. Review.</citation>
    <PMID>16282086</PMID>
  </reference>
  <reference>
    <citation>Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15(6):453-67. Review.</citation>
    <PMID>11524024</PMID>
  </reference>
  <reference>
    <citation>Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003 Oct;98(10):1403-7.</citation>
    <PMID>14519177</PMID>
  </reference>
  <reference>
    <citation>Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2000 Nov 13;160(20):3128-34.</citation>
    <PMID>11074742</PMID>
  </reference>
  <reference>
    <citation>Cinciripini PM, Tsoh JY, Wetter DW, Lam C, de Moor C, Cinciripini L, Baile W, Anderson C, Minna JD. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol. 2005 Nov;13(4):282-92.</citation>
    <PMID>16366758</PMID>
  </reference>
  <reference>
    <citation>Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, Mailliard JA, Ebbert LP, Swan DK, Walsh DJ, Wiesenfeld M, Levitt R, Stella P, Johnson PA, Tschetter LK, Loprinzi C. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res. 2003 Apr;5(2):181-7.</citation>
    <PMID>12745490</PMID>
  </reference>
  <reference>
    <citation>Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007 Feb;82(2):186-95.</citation>
    <PMID>17290726</PMID>
  </reference>
  <reference>
    <citation>Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007 Aug;27(4):380-6.</citation>
    <PMID>17632223</PMID>
  </reference>
  <reference>
    <citation>Fagerström KO, Tönnesen P. Nicotine chewing gum and nicotine patch. Wien Med Wochenschr. 1995;145(4):77-82. Review.</citation>
    <PMID>7778323</PMID>
  </reference>
  <reference>
    <citation>Hall SM, Humfleet GL, Reus VI, Muñoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry. 2004 Nov;161(11):2100-7.</citation>
    <PMID>15514412</PMID>
  </reference>
  <reference>
    <citation>Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 Mar 4;340(9):685-91.</citation>
    <PMID>10053177</PMID>
  </reference>
  <reference>
    <citation>Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol. 2000 Oct;68(5):883-9.</citation>
    <PMID>11068974</PMID>
  </reference>
  <reference>
    <citation>Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, Samuels D, Levin SK, Green S, Schatzberg AF. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol. 2004 Aug;72(4):729-35.</citation>
    <PMID>15301658</PMID>
  </reference>
  <reference>
    <citation>Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995 Jan;24(1):41-7.</citation>
    <PMID>7740014</PMID>
  </reference>
  <reference>
    <citation>Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob Res. 2003 Dec;5(6):851-7.</citation>
    <PMID>14750508</PMID>
  </reference>
  <reference>
    <citation>O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006 Mar 27;166(6):667-74.</citation>
    <PMID>16567607</PMID>
  </reference>
  <reference>
    <citation>Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res. 2007 Sep;9(9):947-54.</citation>
    <PMID>17763111</PMID>
  </reference>
  <reference>
    <citation>Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998 Aug;6(3):331-43.</citation>
    <PMID>9725117</PMID>
  </reference>
  <reference>
    <citation>Williams J, Ziedonis DM. Naltrexone-bupropion combination therapy for protracted abstinence dysphoria. Am J Addict. 2003 May-Jun;12(3):270-2.</citation>
    <PMID>12851023</PMID>
  </reference>
  <reference>
    <citation>Rose JE, Levin ED. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacol Biochem Behav. 1992 Jan;41(1):219-26. Review.</citation>
    <PMID>1539072</PMID>
  </reference>
  <reference>
    <citation>Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995 Sep;56(9):395-401. Review.</citation>
    <PMID>7665537</PMID>
  </reference>
  <reference>
    <citation>Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474-7.</citation>
    <PMID>15887955</PMID>
  </reference>
  <reference>
    <citation>Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006 Jul;6(7):965-81. Review.</citation>
    <PMID>16831112</PMID>
  </reference>
  <reference>
    <citation>Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol. 2005 Sep;10(3):219-31. Review.</citation>
    <PMID>16109583</PMID>
  </reference>
  <reference>
    <citation>Johnston AJ, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs. 2002;62 Suppl 2:11-24. Review.</citation>
    <PMID>12109932</PMID>
  </reference>
  <reference>
    <citation>Bondarev ML, Bondareva TS, Young R, Glennon RA. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003 Aug 1;474(1):85-93.</citation>
    <PMID>12909199</PMID>
  </reference>
  <reference>
    <citation>Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003 Feb;5(1):13-25. Erratum in: Nicotine Tob Res. 2003 Aug;5(4):603.</citation>
    <PMID>12745503</PMID>
  </reference>
  <reference>
    <citation>SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002 May;4(2):149-59.</citation>
    <PMID>12028847</PMID>
  </reference>
  <reference>
    <citation>Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.</citation>
    <PMID>1932883</PMID>
  </reference>
  <reference>
    <citation>Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl). 2000 Jan;148(1):33-40.</citation>
    <PMID>10663415</PMID>
  </reference>
  <reference>
    <citation>Kotlyar M, Brauer LH, al'absi M, Adson DE, Robiner W, Thuras P, Harris J, Finocchi ME, Bronars CA, Candell S, Hatsukami DK. Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal. Pharmacol Biochem Behav. 2006 Mar;83(3):370-9. Epub 2006 Mar 6.</citation>
    <PMID>16581115</PMID>
  </reference>
  <reference>
    <citation>Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):47-55.</citation>
    <PMID>16820546</PMID>
  </reference>
  <reference>
    <citation>Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.</citation>
    <PMID>16820547</PMID>
  </reference>
  <reference>
    <citation>Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006 Aug 14-28;166(15):1561-8.</citation>
    <PMID>16908788</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>November 14, 2017</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Smoking</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Human laboratory study</keyword>
  <keyword>Stress tolerance</keyword>
  <keyword>Startle response</keyword>
  <keyword>Cognitive assessment</keyword>
  <keyword>Progressive ratio</keyword>
  <keyword>Motivation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion + Placebo Varenicline</title>
          <description>Order 1: Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
        </group>
        <group group_id="P2">
          <title>Varenicline + Placebo Bupropion</title>
          <description>Order 1: Bupropion + Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion + Placebo Varenicline</title>
          <description>Order 1: Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
        </group>
        <group group_id="B2">
          <title>Upropion + Varenicline</title>
          <description>Order 1: Bupropion + Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="11.2"/>
                    <measurement group_id="B2" value="40.2" spread="11.3"/>
                    <measurement group_id="B3" value="39.85" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Count of particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nicotine Withdrawal and Craving</title>
        <description>Subjects were analyzed by how they self reported withdrawal or craved cigarettes during treatment Subjects self reported during study visits along with surveys</description>
        <time_frame>Change from Base line to 33 weeks</time_frame>
        <population>All efforts were made to contact the PI/study team members, but were unsuccessful. No outcome measure study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion + Placebo Varenicline</title>
            <description>Order 1: Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline + Placebo Bupropion</title>
            <description>Order 1: Bupropion + Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Nicotine Withdrawal and Craving</title>
          <description>Subjects were analyzed by how they self reported withdrawal or craved cigarettes during treatment Subjects self reported during study visits along with surveys</description>
          <population>All efforts were made to contact the PI/study team members, but were unsuccessful. No outcome measure study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two tailed testing</non_inferiority_desc>
            <p_value>0.07</p_value>
            <method>SAS</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupropion + Placebo Varenicline</title>
          <description>Order 1: Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
        </group>
        <group group_id="E2">
          <title>Varenicline + Placebo Bupropion</title>
          <description>Order 1: Bupropion + Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Varenicline&#xD;
Bupropion SR: Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.&#xD;
Varenicline: Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>.05</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Mooney PhD</name_or_title>
      <organization>University of Minnesota</organization>
      <email>moon0078@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

